Titan Pharmaceuticals Announces Successful Merger
Titan Pharmaceuticals, Inc. has officially closed its merger with Black Titan Corporation and TalenTec Sdn. Bhd. This significant move marks a new era for the combined entities, with Titan trading under the ticker symbol NASDAQ: BTTC. Stakeholders can expect considerable changes and growth in the coming periods as the two companies form a unified front.
Details of the Merger
Under the terms set forth in the Merger and Contribution and Share Exchange Agreement, Titan becomes a wholly owned subsidiary of Black Titan. This change took effect at the beginning of October, signaling a pivotal moment in the companies’ histories. The arrangement involved the conversion of each Titan common stock share into an equivalent share of Black Titan, ensuring a seamless transition for stakeholders.
Trading Changes
As announced, trading of Titan's shares on the Nasdaq Capital Market has ceased. However, Black Titan's ordinary shares started trading on Nasdaq as a new entity, reinforcing its position within the market. This pivotal shift is expected to create more opportunities for investors and stakeholders going forward.
Strategic Vision Ahead
Chay W. J., the CEO of Black Titan, elaborated on the significance of the merger, expressing enthusiasm for the path that lies ahead. He indicated that this union is just the beginning of a dynamic strategy aimed at fostering innovation and initiating global expansion. The objective is clear: to deliver transformative value to all stakeholders.
Financial Advisory Team
In the backdrop of this major transition, ARC Group Ltd. played a crucial role by serving as the exclusive financial advisor to Black Titan Corporation. Their expertise brought strategic insight into the merger, aiming to maximize the benefits for both parties involved.
Focus on Future Growth
The merger not only combines two significant players in the pharmaceutical landscape but also sets the stage for expansive growth. With the synergistic strengths of both Titan and Black Titan working together, there is a promise of developing new and innovative solutions that could redefine the market.
Contact Information
For further inquiries regarding the merger and future implications, stakeholders can reach out directly to the CEO, Chay W. J., at (786) 769-7512. This contact will be vital for investors eager to understand the strategic changes and their effects on stock performance.
Frequently Asked Questions
What is Titan Pharmaceuticals' new corporate structure following the merger?
Titan Pharmaceuticals is now a wholly-owned subsidiary of Black Titan Corporation, enhancing its operational capacity.
When did the trading transition take place?
Trading for Titan's common stock ended on October 1, 2025, and trading for Black Titan began on October 2, 2025.
Who is the CEO of the combined corporation?
Chay W. J. serves as the Chief Executive Officer of Black Titan Corporation post-merger.
What is the expected impact of the merger for shareholders?
Shareholders can anticipate new opportunities and enhanced value as the companies work together to execute their strategic vision.
How can investors learn more about future developments?
Investors can contact CEO Chay W. J. directly for more information regarding the merger and its implications.
